Equecabtagene autoleucel (eque-cel), a fully human BCMA-targeted CAR-T cell therapy, was approved by NMPA in June 2023 for adult relapsed/refractory multiple myeloma patients after ≥3 prior lines of therapy. Here, TNFRSF17 is linked to plasma cell myeloma.